Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-miR-194
- Development stage
- Preclinical
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intratumoral, Parenteral, Intrathecal, Subcutaneous, Intraperitoneal
01
Overview
anti-miR-194 is an antisense oligonucleotide (antagomir) designed to competitively bind and inhibit the activity of microRNA-194 (miR-194). In various cancers, including endometrial and colorectal cancers, miR-194 is frequently overexpressed and acts as an oncomiR by promoting cell migration, invasion, and epithelial-mesenchymal transition (EMT). By sequestering mature miR-194, anti-miR-194 restores the expression of target genes that suppress tumor progression. While primarily utilized as a research tool to validate miR-194 as a therapeutic target, the modality represents a class of RNA-targeted therapies aimed at modulating oncogenic miRNA signatures.
- Other names
- miR-194 inhibitormiR194 inhibitormiR 194 inhibitorantagomir-194antagomir194antagomir 194anti-microRNA-194anti-microRNA194anti-microRNA 194
02
Targets
miR-194-3p (MicroRNA 194-3p)miR-194-5p (MicroRNA 194-5p)
Beyond the preview
Go deeper on anti-miR-194.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-miR-194.